Letter to the Editor
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 14, 2023; 29(46): 6089-6091
Published online Dec 14, 2023. doi: 10.3748/wjg.v29.i46.6089
Albumin-bilirubin score in non-malignant liver diseases should be properly validated
Andrea Pasta, Francesco Calabrese, Maria Corina Plaz Torres, Giorgia Bodini, Manuele Furnari, Edoardo Vincenzo Savarino, Vincenzo Savarino, Edoardo Giovanni Giannini, Elisa Marabotto
Andrea Pasta, Francesco Calabrese, Maria Corina Plaz Torres, Giorgia Bodini, Manuele Furnari, Vincenzo Savarino, Edoardo Giovanni Giannini, Elisa Marabotto, Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS‐Ospedale Policlinico San Martino, Genoa 16132, Italy
Edoardo Vincenzo Savarino, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padua, Padua 35128, Italy
Co-first authors: Andrea Pasta and Francesco Calabrese.
Author contributions: Pasta A and Calabrese F contributed equally to the manuscript; Pasta A and Calabrese F designed and performed research; Pasta A and Calabrese F wrote the letter; Plaz Torres MC, Bodini G, Furnari M, Savarino V, Giannini EG, Savarino EV and Marabotto E revised the letter.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Elisa Marabotto, MD, PhD, Academic Research, Doctor, Professor, Researcher, Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS‐Ospedale Policlinico San Martino, Viale Benedetto XV, 6, Genoa 16132, Italy. elisa.marabotto@unige.it
Received: September 20, 2023
Peer-review started: September 20, 2023
First decision: October 12, 2023
Revised: October 25, 2023
Accepted: November 17, 2023
Article in press: November 17, 2023
Published online: December 14, 2023
Processing time: 83 Days and 12.5 Hours
Core Tip

Core Tip: The albumin-bilirubin (ALBI) score was initially proposed to evaluate liver function in patients with hepatocellular carcinoma. It proposed to validate the ALBI score to assess the risk of decompensation in patients with compensated cirrhosis. We provide a comment to highlight the preliminary nature of the evidence reported by the authors. Further studies are needed to validate the ALBI score to predict decompensation in patients with cirrhosis.